Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 September 2021 | Story Michelle Nöthling | Photo Supplied
Lerato Sheila Thamahane.

Lerato Thamahane may be able to speak and understand all nine of South Africa’s official African languages, but it is a tenth language she is devoting her life to: South African Sign Language (SASL).

With nearly ten years’ experience as a SASL interpreter in several settings – ranging from the medical and mental-health fields to that of conferences and Deafblind interpreting – Lerato is living her life’s purpose. “I regard myself as a member of the Deaf community and a servant at the same time.”

Lerato lives by the principle that the more perspectives she gains on the world, the better service as an interpreter she can provide. This is also part of the reason why Lerato decided to take on the role of student again to study BA Language Practice to provide her with an even broader perspective on the field. 

But why does Lerato feel so strongly about SASL? It is only through Sign Language, Lerato explains, that one can bridge the divide between the world of the hearing and that of the Deaf. “SASL is the only way for the minority Deaf group to receive and transfer information,” Lerato emphasises. “Deaf people cannot communicate in any other way.” Now, consider for a moment the plight of a Deaf child in South Africa. To receive education in SASL, most Deaf children have to move far away from home at a very young age in order to attend a school for the Deaf. For many years, schools for the Deaf did not include other languages as subjects, which prevented Deaf school-leavers from entering higher education. Although this situation has largely changed, Deaf students are still fighting an uphill battle when entering higher education institutions where prejudice and ignorance still persist. This is where the work of the Centre for Universal Access and Disability Support (CUADS) and the Department of South African Sign Language (SASL) and Deaf Studies makes such a crucial difference.

“I firmly believe,” Lerato says, “that only Sign Language can open opportunities for all groups of the Deaf community – from Deaf children to adults, and from the uneducated to the most educated Deaf people.” It is for this reason, Lerato argues, that our constitution needs to recognise SASL in order to give Deaf people full and equal access to information, to education, and ultimately, to all the opportunities South Africa has to offer.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept